Stocks › M › MPXEF

MPX Bioceutical Corporation (MPXEF) — Earnings Call X-Ray

Our AI read all 2 of MPXEF's earnings calls (2018–2018) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q1 2019 · sign up to see
Previous Call Grade
C+
Q2 2018
Expected Move
🔒
next 45 days · members
Calls Analyzed
2
2018–2018
Avg Candor
7/9
evasion 3/9
Guidance RaisedHigh CandorCritic AmmunitionVolume Step-UpEarly Product, Fast GrowthUnderused Fixed CostsPricing Under PressureMargins Contracting

Call-by-call analysis

🔒 Q1 2019 earnings call 2018-08-30 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor ■/9
Specificity ■/9
Evasion ■/9
Stress ■/9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q1 2019 call grade is ready
The full 37-point AI read of MPXEF's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

C+ Q2 2018 earnings call 2018-08-06

Management raised guidance against accelerating demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: acceleratingMargins: contractingPricing: under pressureHeadcount: growingCapex: increasing 3 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growthDirection beats results
Candor 8/9
Specificity 7/9
Evasion 2/9
Confidence 7/9
Uncertainty 4/9
Promotion 5/9
Stress 4/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AA · Alcoa CorporationAAALF · Aareal Bank AGAABKF · Aareal Bank AGAAGIY · AIA Group LimitedAAL · American Airlines Group AAPL · Apple Inc.

← MPX   All “M” companies    MPXOF →

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.